Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells?

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Moll, Guido ^a   Hult, Annika ^b   Von Bahr, Lena ^a,c   Alm, Jessica J ^a   Heldring, Nina ^a   Hamad, Osama A ^d   Stenbeck Funke, Lillemor ^d   Larsson, Stella ^a   Teramura, Yuji ^d   Roelofs, Helene ^e   Nilsson, Bo ^d   Fibbe, Willem E ^e   Olsson, Martin L ^b   Le Blanc, Katarina ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP A ANTIBODY; BLOOD GROUP A ANTIGEN; BLOOD GROUP ANTIBODY; BLOOD GROUP B ANTIBODY; BLOOD GROUP B ANTIGEN; BLOOD GROUP O ANTIBODY; BLOOD GROUP O ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; BLOOD GROUP ABO SYSTEM; CELL THERAPY; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STROMA CELL; MIDDLE AGED; PRESCHOOL CHILD;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADSORPTION; ADULT; AGED; ANTIBODIES; CELLS, CULTURED; CHILD; DNA METHYLATION; GENOTYPE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TREATMENT OUTCOME; UP-REGULATION;

EID: 84898007335     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085040     Document Type: Article

References (37)

1. Singer NG, Caplan AI (2011) Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 6: 457-478.
2. Ankrum J, Karp JM (2010) Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 16: 203-209.
3. Galipeau J (2013) The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 15: 2-8.
4. Phinney DG, Sensebe L (2013) Mesenchymal stromal cells: misconceptions and evolving concepts. Cytotherapy 15: 140-145.
5. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, et al. (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371: 1579-1586. (Pubitemid 351626841)
6. von Bahr L, Sundberg B, Lonnies L, Sander B, Karbach H, et al. (2012) Longterm complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 18: 557-564.
7. Moll G, Rasmusson-Duprez I, von Bahr L, Connolly-Andersen AM, Elgue G, et al. (2012) Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells 30: 1565-1574.
8. Galili U (2006) Xenotransplantation and ABO incompatible transplantation: the similarities they share. Transfus Apher Sci 35: 45-58.
9. Storry JR, Olsson ML (2009) The ABO blood group system revisited: a review and update. Immunohematology 25: 48-59.
10. Bianco-Miotto T, Hussey DJ, Day TK, O'Keefe DS, Dobrovic A (2009) DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients. PLoS ONE 4: e4788.
11. Orntoft TF, Meldgaard P, Pedersen B, Wolf H (1996) The blood group ABO gene transcript is down-regulated in human bladder tumors and growthstimulated urothelial cell lines. Cancer Res 56: 1031-1036. (Pubitemid 26065396)
12. Olsson ML, Irshaid NM, Hosseini-Maaf B, Hellberg A, Moulds MK, et al. (2001) Genomic analysis of clinical samples with serologic ABO blood grouping discrepancies: identification of 15 novel A and B subgroup alleles. Blood 98: 1585-1593.
13. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, et al. (2004) Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 9: 747-756. (Pubitemid 38660428)
14. Kocaoemer A, Kern S, Kluter H, Bieback K (2007) Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 25: 1270-1278. (Pubitemid 46684887)
15. Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, et al. (2009) Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 27: 2331-2341.
16. Schallmoser K, Strunk D (2013) Generation of a pool of human platelet lysate and efficient use in cell culture. Methods Mol Biol 946: 349-362.
17. Fekete N, Gadelorge M, Furst D, Maurer C, Dausend J, et al. (2012) Platelet lysate from whole blood-derived pooled platelet concentrates and apheresisderived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 14: 540-554.
18. Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, et al. (2007) No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 92: 1208-1215. (Pubitemid 350144179)
19. Schafer R, Schnaidt M, Klaffschenkel RA, Siegel G, Schule M, et al. (2011) Expression of blood group genes by mesenchymal stem cells. Br J Haematol 153: 520-528.
20. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, et al. (2002) Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 99: 8932-8937. (Pubitemid 34693661)
21. Toki D, Ishida H, Horita S, Yamaguchi Y, Tanabe K (2009) Blood group O recipients associated with early graft deterioration in living ABO-incompatible kidney transplantation. Transplantation 88: 1186-1193.
22. Ringden O, Leblanc K (2011) Pooled MSCs for treatment of severe hemorrhage. Bone Marrow Transplant 46: 1158-1160.
23. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57: 11-20. (Pubitemid 38019084)
24. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, et al. (2007) Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21: 1733-1738. (Pubitemid 47086763)
25. Hosseini-Maaf B, Hellberg A, Chester MA, Olsson ML (2007) An extensive polymerase chain reaction-allele-specific polymorphism strategy for clinical ABO blood group genotyping that avoids potential errors caused by null, subgroup, and hybrid alleles. Transfusion 47: 2110-2125. (Pubitemid 47623981)
26. Olsson ML, Chester MA (1995) A rapid and simple ABO genotype screening method using a novel B/O2 versus A/O2 discriminating nucleotide substitution at the ABO locus. Vox Sang 69: 242-247.
27. Connolly-Andersen AM, Moll G, Andersson C, Akerstrom S, Karlberg H, et al. (2011) Crimean-Congo hemorrhagic fever virus activates endothelial cells. J Virol 85: 7766-7774.
28. Liu QP, Sulzenbacher G, Yuan H, Bennett EP, Pietz G, et al. (2007) Bacterial glycosidases for the production of universal red blood cells. Nat Biotechnol 25: 454-464. (Pubitemid 46572854)
29. Nilsson B, Larsson R, Hong J, Elgue G, Ekdahl KN, et al. (1998) Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 92: 1661-1667. (Pubitemid 28406870)
30. Bennet W, Sundberg B, Groth CG, Brendel MD, Brandhorst D, et al. (1999) Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes 48: 1907-1914. (Pubitemid 29458351)
31. Gustafson EK, Elgue G, Hughes RD, Mitry RR, Sanchez J, et al. (2011) The instant blood-mediated inflammatory reaction characterized in hepatocyte transplantation. Transplantation 91: 632-638.
32. Deak E, Ruster B, Keller L, Eckert K, Fichtner I, et al. (2010) Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice. Cytotherapy 12: 260-264.
33. Hakomori S (1999) Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta 1473: 247-266.
34. Hirvonen T, Suila H, Kotovuori A, Ritamo I, Heiskanen A, et al. (2012) The i blood group antigen as a marker for umbilical cord blood-derived mesenchymal stem cells. Stem Cells Dev 21: 455-464.
35. Heiskanen A, Hirvonen T, Salo H, Impola U, Olonen A, et al. (2009) Glycomics of bone marrow-derived mesenchymal stem cells can be used to evaluate their cellular differentiation stage. Glycoconj J 26: 367-384.
36. Nilsson B, Korsgren O, Lambris JD, Ekdahl KN (2010) Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? Trends Immunol 31: 32-38.
37. Stussi G, Mueller RJ, Passweg J, Schanz U, Rieben R, et al. (2007) ABO blood group incompatible haematopoietic stem cell transplantation and xenograft rejection. Swiss Med Wkly 137 Suppl 155: 101S-108S.